Xianhe Bai
Emory University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xianhe Bai.
American Journal of Pathology | 2000
Jack L. Arbiser; Helena Larsson; Lena Claesson-Welsh; Xianhe Bai; Kenneth R. LaMontagne; Sharon W. Weiss; Shai Soker; Evelyn Flynn; Lawrence F. Brown
Vascular endothelial growth factor (VEGF or vascular permeability factor) is an important angiogenic factor that is up-regulated in numerous benign and malignant disorders, including angiosarcoma, hemangiomas, and solid tumors. To determine the functional role of VEGF in the development of endothelial tumors, we expressed primate VEGF 121 in an endothelial cell line, MS1, derived from primary murine cells by immortalization with a temperature-sensitive SV40 large T antigen. This cell line expresses the VEGFR-2 (Flk-1/Kdr) receptor for VEGF. Expression of VEGF 121 led to the development of slowly growing endothelial tumors, which were histologically well-differentiated angiosarcomas. The angiosarcomas generated from MS1 VEGF cells demonstrated up-regulation of the VEGF receptors VEGFR-2 and VEGFR-1 (Flt-1) in vivo compared with benign hemangiomas generated from MS1 cells. Treatment of these cells with the VEGFR-2 tyrosine kinase inhibitor SU 1498 led to decreased expression of ets-1, a transcription factor which has been shown to be stimulated by VEGF. These results suggest that high level expression of VEGF in endothelial cells may result in malignant transformation. This transformation process likely involves both autocrine and paracrine pathways.
Bioorganic & Medicinal Chemistry Letters | 2003
Thomas Philip Robinson; Tedman Ehlers; Richard Hubbard; Xianhe Bai; Jack L. Arbiser; David J. Goldsmith; J. Phillip Bowen
The quest to find new antitumor compounds is an ongoing research endeavor in many laboratories around the world. The use of small-molecule angiogenesis inhibitors promises to be a potentially effective method for cancer treatment and possible prevention. Many antiangiogenic compounds are in various stages of laboratory evaluations and clinical trials. Curcumin is a natural product that has exhibited potent antiangiogenic properties. Based on a simple pharmacophore model, using standard drug design concepts, aromatic enone and aromatic dienone analogues of curcumin were prepared and/or obtained commercially. These compounds were screened for antiangiogenic properties via an in vitro SVR assay and were found to inhibit cell proliferation.
American Journal of Pathology | 2001
Jack L. Arbiser; Raymond S. Yeung; Sharon W. Weiss; Zoya K. Arbiser; Mahul B. Amin; Cynthia Cohen; David A. Frank; Sudipta Mahajan; G. Scott Herron; Jiwei Yang; Hiroki Onda; Hailei Zhang; Xianhe Bai; Erik J. Uhlmann; Allison Loehr; Hope Northrup; Paul Au; Ian J. Davis; David E. Fisher; David H. Gutmann
Angiomyolipomas are benign tumors of the kidney derived from putative perivascular epithelioid cells, that may undergo differentiation into cells with features of melanocytes, smooth muscle, and fat. To gain further insight into angiomyolipomas, we have generated the first human angiomyolipoma cell line by sequential introduction of SV40 large T antigen and human telomerase into human angiomyolipoma cells. These cells show phenotypic characteristics of angiomyolipomas, namely differentiation markers of smooth muscle (smooth muscle actin), adipose tissue (peroxisome proliferator-activator receptor gamma, PPARgamma), and melanocytes (microophthalmia, MITF), thus demonstrating that a single cell type can exhibit all of these phenotypes. These cells should serve as a valuable tool to elucidate signal transduction pathways underlying renal angiomyolipomas.
American Journal of Pathology | 2002
Jack L. Arbiser; Baskaran Govindarajan; Xianhe Bai; Hiroaki Onda; Andrius Kazlauskas; So Dug Lim; Mahul B. Amin; Lena Claesson-Welsh
Tumors often exhibit activation of specific tyrosine kinases, which may allow targeting of therapy through inhibition of tyrosine kinase signaling. This strategy has been used successfully in the development of STI571 (gleevec), an inhibitor of bcr-abl tyrosine kinase that has been used successfully in the treatment of chronic myelogenous leukemia. STI571 also shows activity against c-kit and platelet-derived growth factor receptor-beta (PDGFRbeta) tyrosine kinase signaling, thus potentially expanding the number of tumors that may respond to it. We describe a simple and rapid method to assess functional activity of tyrosine kinase signaling that is broadly applicable to tumor types. As proof of principle, we have applied it to cells that serve as models of the autosomal-dominant tumor syndrome tuberous sclerosis (TS). We found that TS model cells derived from tuberin heterozygous mice and from a human renal angiomyolipoma are highly sensitive to PDGFR antagonists and that these cells express PDGFRbeta. Given that PDGFRbeta signaling is inhibited by STI571, we found that SV7tert human angiomyolipoma cells are sensitive to STI571. Thus, we describe a novel but simple method of determining the functional tyrosine kinase profile of a neoplastic cell and our results suggest that STI571 might be useful in the treatment of neoplasms commonly seen in patients with TS.
Experimental Cell Research | 2003
Emma Rennel; Michael J. Cross; Peter Klint; Xianhe Bai; Jack L. Arbiser; Pär Gerwins
Angiogenesis is regulated by growth factors which activate tyrosine kinase receptors leading to the activation of a number of intracellular signaling pathways. The specific function of H-Ras during FGF-2 stimulated endothelial cell differentiation, defined as invasive growth and formation of branching networks in fibrin gels, was investigated by using conditionally immortalized endothelial cell lines induced to express H-Ras mutants. Expression of inhibitory N17Ras did not impair differentiation in response to FGF-2 and TNF-alpha. The farnesyltransferase inhibitor FTI-277 inhibited farnesylation of Ras but did not inhibit differentiation of human microvascular endothelial cells or mouse brain endothelial cells. In contrast, activated V12Ras inhibited endothelial cell differentiation and cells displayed a transformed phenotype with an increased rate of proliferation and loss of contact inhibited growth. Furthermore, V12Ras expressing endothelial cells grew as solid tumors when injected subcutaneously into mice. Our data suggest that, in endothelial cells, H-Ras activity is not required for differentiation. However, this activity must be tightly regulated as aberrant activity can disturb the ability of endothelial cells to undergo differentiation.
Journal of Biological Chemistry | 2003
Xianhe Bai; Francesca Cerimele; Masuko Ushio-Fukai; Muhammad Waqas; Paul M. Campbell; Baskaran Govindarajan; Channing J. Der; Traci E. Battle; David A. Frank; Keqiang Ye; Emma Murad; Wolfgang Dubiel; Gerald A. Soff; Jack L. Arbiser
Molecular Medicine | 2002
Baskaran Govindarajan; Robert Klafter; Mark Steven Miller; Claire Mansur; Melissa Mizesko; Xianhe Bai; Kenneth R. LaMontagne; Jack L. Arbiser
Journal of Biological Chemistry | 2003
Baskaran Govindarajan; Xianhe Bai; Cynthia Cohen; Hua Zhong; Susan Kilroy; Gwendolyn Louis; Marsha A. Moses; Jack L. Arbiser
Journal of The American Academy of Dermatology | 2002
Jack L. Arbiser; Daniel J. Brat; Steve Hunter; Jeanine D'Armiento; Elizabeth P. Henske; Zoya K. Arbiser; Xianhe Bai; Gerald Goldberg; Cynthia Cohen; Sharon W. Weiss
Archive | 2002
Jack L. Arbiser; Xianhe Bai